ClinicalTrials.gg
CompletedNCT06813781Updated Oct 15, 2025

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

A Phase 1 interventional study of AZD5004 in Hepatic Impairment, sponsored by AstraZeneca. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.

Read the detailed description

This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, or severe hepatic impairment compared with participants with normal hepatic function.

Participants will be enrolled within the following groups based on their Child Pugh classification score as determined at screening:

Group 1: Participants with mild hepatic impairment (Child Pugh Class A, score of 5 or 6).

Group 2: Participants with moderate hepatic impairment (Child Pugh Class B, score of 7 to 9).

Group 3: Participants with severe hepatic impairment (Child Pugh Class C, score of 10 to 15).

Group 4: Participants with normal hepatic function matched on a group level regarding sex, age, and body weight to the impaired participants.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • Hepatic Impairment
  • Healthy participants
  • AZD5004
  • Pharmacokinetics
  • Safety
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For ALL participants:

  • Adults 18-80 years of age
  • Weight ≥50kg and between ≥18 to ≤40 kg/m2 For participants with normal hepatic function:
  • Participant must be stable on a concomitant medication and/or treatment regimen for at least 2 weeks prior to screening

For Healthy Controls:

-Participant must be medically healthy with no significant findings on medical evaluation at screening to include but not limited to an >90 ml/min/1.73 m2

For participants with hepatic impairment:

  • Group 1 (mild) must have an score of 5 or 6, Group 2 (moderate) must have a Child-Pugh score of 7 to 9, Group 3 (severe) must have a Child-Pugh score of 10 to 15.
  • Participant must have a diagnosis of chronic (≥ 6 months) and stable hepatic impairment (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study screening

Exclusion criteria

Exclusion Criteria:

For ALL participants:

  • Poorly controlled diabetes mellitus ( >10% at screening).
  • Unwillingness to use adequate
  • Uncontrolled hypertension or hypotension
  • Presence of unstable systemic disease or psychologic conditions.
  • Any abnormalities in rhythm, conduction, or morphology of the resting and any clinically important abnormalities in the 12-lead ECG.

Specific For Healthy Controls:

-Positive screening for , , or -

-Any clinically significant disease or disorder to include but not limited to acute or chronic liver disease

Specific For Hepatically Impaired Participants:

  • \<60 ml/min/1.73 m2
  • Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment to include rising LFTs, paracentesis at less than 4 week intervals, oesophageal banding within the last 3 months, or treatment for GI bleeding within the last 6 months
  • Presence of a hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Group 1

    A single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

  • Experimental
    Group 2

    A single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

  • Experimental
    Group 3

    A single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

  • Experimental
    Group 4

    A single oral dose of AZD5004 under fasted conditions.

    Drug: AZD5004

Interventions

  • Dose 1

    Also known as: ECC5004, Dose 1

06

What researchers measure

Primary outcomes

  1. AUCinf

    Area under plasma concentration-time curve from zero to infinity

    Time frame: Day 1 to Day 6

  2. AUClast

    Area under plasma concentration-time curve from time zero to the last measurable concentration

    Time frame: Day 1 to Day 6

  3. Cmax

    Maximum observed plasma concentration

    Time frame: Day 1 to Day 6

Secondary outcomes

  1. Tmax

    Time to reach maximum observed plasma concentration

    Time frame: Day 1 to Day 6

  2. PK parameters (t1/2λz)

    Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve

    Time frame: Day 1 to Day 6

  3. PK parameters CL/F

    Apparent total body clearance of drug from plasma after extravascular administration

    Time frame: Day 1 to Day 6

  4. PK parameters CLNR/F

    Non-renal clearance of drug from plasma after oral administration

    Time frame: Day 1 to Day 6

  5. PK parameter Vz/F

    Apparent volume of distribution during the terminal phase after extravascular administration

    Time frame: Day 1 to Day 6

  6. PK parameter CLr

    Renal clearance of the drug from plasma

    Time frame: Day 1 to Day 6

  7. PK parameter Ae

    Cumulative amount of unchanged drug excreted into the urine

    Time frame: Day 1 to Day 6

  8. fe

    Fraction of the drug excreted into the urine

    Time frame: Day 1 to Day 6

Other outcomes

  1. Number of participants with adverse events (AEs)

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 10

  2. Participants with abnormal blood pressure

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

  3. Number of participants with abnormal laboratory tests results

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

  4. Number of participants with serious adverse events (SAEs)

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 10

  5. Participants with abnormal ECG QTcF findings

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

  6. Participants with abnormal physical examination findings

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

  7. Participants with abnormal heart rate

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

  8. Number of participants with abnormal ECG PR interval findings

    To assess the safety and tolerability of a single oral dose of AZD5004 for participants with mild, moderate, and severe hepatic impairment and those with normal hepatic function

    Time frame: Day 1 to Day 6

07

Study locations

5 sites
  • Research Site
    Lake Forest, California 92630, United States
  • Research Site
    Rialto, California 92377, United States
  • Research Site
    Miami Lakes, Florida 33014, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    San Antonio, Texas 78215, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Oct 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Feb 7, 2025
StartActual
Dec 19, 2024
Primary completionActual
Oct 2, 2025
CompletionActual
Oct 2, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06813781
Lead sponsor
AstraZeneca
Collaborators
Fortrea Clinical Research Unit Inc.
Responsible party
Sponsor
First posted
Feb 7, 2025
Start date
Dec 19, 2024
Primary completion
Oct 2, 2025
Completion
Oct 2, 2025
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion